Business
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference
If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per yearREC-2282 has been granted Fast Track and Orphan Drug designations for NF2 meningiomas by the U.S. Food and Drug Administration, as well as Orphan Drug designation for NF2 meningiomas by the European CommissionSALT LAKE CITY, June 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation of its Phase 2/3 POPLAR-NF2 clinical trial during the Children's Tumor Foundation NF Conference. The trial will evaluate REC-2282: a potentially first-in-disease, orally bioavailable, central nervous system (CNS) penetrant small molecule histone deacetylase (HDAC) inhibitor, for the treatment of progressive neurofibromatosis type 2 (NF2)-mutated meningiomas.\n\n \n \n \n \n \n \n\n \nThe study is actively enrolling patients who meet criteria including the following:\n>12 years of age and weighing at least 40 kgProgressive meningioma that is amenable to volumetric analysisHas either 1) sporadic meningioma with confirmed NF2 mutation; or, 2) confirmed diagnosis of NF2 disease (revised Manchester criteria); or, 3) at least one NF2-related tumor (with pathogenic germline or proven mosaic NF2 variant)There are currently no FDA-approved drugs for the treatment of patients with NF2, an inherited genetic syndrome that can cause a variety of benign tumors in the central nervous system, including meningiomas. Recursion discovered REC-2282 as a potential candidate for treatment of disease resulting from mutation in the NF2 gene by leveraging its proprietary AI-powered drug discovery platform, the Recursion OS. We believe this approach, in which machine learning is used to identify relationships between biological contexts and chemical entities, will enable Recursion to accelerate the drug discovery process and expand the scope of potential therapeutic candidates for numerous diseases.\n\"We are currently crying out for a therapy for inoperable meningiomas and in particular the multiple meningiomas that we see in neurofibromatosis type 2 that cause so much morbidity and ultimately mortality,\" said Professor Gareth Evans, Manchester University NHS Foundation Trust, St. Mar...